Gelonghui, April 22丨Hysen Pharmaceutical (001367.SZ) announced its 2023 annual report. Operating income for the reporting period was 397 million yuan, down 5.99% year on year; net profit attributable to shareholders of listed companies was 105 million yuan, down 2.72% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 101 million yuan, down 0.14% year on year; basic income per share was 1.68 yuan; it plans to distribute a cash dividend of 5 yuan (tax included) for every 10 shares to all shareholders.
海森药业(001367.SZ)：2023年度净利润1.05亿元 拟10转4.8派5元
Hisense Pharmaceutical (001367.SZ): Net profit of 105 million yuan in 2023, plans to convert 10 to 4.8 to 5 yuan
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.